Please provide your email address to receive an email when new articles are posted on . Remdesivir did not reduce adverse cardiovascular or kidney events in the study cohort. Remdesivir use was ...

Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

Having a cystatin C-based eGFR value at least 30% lower than creatinine-based eGFR is associated with increased risks of early death, cardiovascular events, and kidney failure requiring replacement ...

For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

This study has three key findings. First, although metformin use has increased in the past decade for treatment of the general population with type 2 diabetes, it remains underused among individuals ...

The relationship between cardiovascular dysfunction and renal impairment is widely recognized as the cardiorenal interaction, ...

ORLANDO -- Even type 2 diabetes patients with impaired renal function saw improvements in weight and glycemic control with a dual SGLT1/2 inhibitor, according to a meta-analysis. Among nearly 4,000 ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has ...